1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2016

Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2016" provides an overview of Von Hippel-Lindau Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Von Hippel-Lindau Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Europe 8
Top Countries Contributing to Clinical Trials in North America 9
Clinical Trials by G7 Countries: Proportion of Von Hippel-Lindau Syndrome to Genetic Disorders Clinical Trials 10
Clinical Trials by Phase in G7 Countries 11
Clinical Trials in G7 Countries by Trial Status 12
Clinical Trials by Phase 13
In Progress Trials by Phase 14
Clinical Trials by Trial Status 15
Clinical Trials by End Point Status 16
Subjects Recruited Over a Period of Time 17
Clinical Trials by Sponsor Type 18
Prominent Sponsors 19
Top Companies Participating in Von Hippel-Lindau Syndrome Therapeutics Clinical Trials 20
Prominent Drugs 21
Clinical Trial Profile Snapshots 22
Appendix 39
Abbreviations 39
Definitions 39
Research Methodology 40
Secondary Research 40
About GlobalData 41
Contact Us 41
Disclaimer 41
Source 42

List of Tables
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Region, 2016* 5
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Europe, Top Countries, 2016* 8
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2016* 9
Proportion of Von Hippel-Lindau Syndrome to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 10
Von Hippel-Lindau Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 11
Von Hippel-Lindau Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 12
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Phase, 2016* 13
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 14
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 15
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016* 16
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 17
Von Hippel-Lindau Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 18
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 19
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 20
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 21

List of Figures
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Europe, Top Countries (%), 2016* 8
Proportion of Von Hippel-Lindau Syndrome to Genetic Disorders Clinical Trials, G7 Countries (%), 2016* 10
Von Hippel-Lindau Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 11
Von Hippel-Lindau Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 12
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2016* 13
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 14
Von Hippel-Lindau Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 15
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016* 16
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 17
Von Hippel-Lindau Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 18
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 19
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 20
Von Hippel-Lindau Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 21
GlobalData Methodology 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

Protein Labeling Market by Product, Labeling Method, Application, & Region - Global Forecast to 2020

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global protein labeling market is expected to reach USD 1,894.5 million by 2020 from USD 1,089.5 million in 2015, at a CAGR of 11.7% from 2015 to 2020. On the basis of products, the protein labeling ...

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Global Pea Protein Market

October 2016 $ 4250

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.